• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Setting future standards for KRAS testing in colorectal cancer.

作者信息

van Krieken Han, Tol Jolien

出版信息

Pharmacogenomics. 2009 Jan;10(1):1-3. doi: 10.2217/14622416.10.1.1.

DOI:10.2217/14622416.10.1.1
PMID:19102707
Abstract
摘要

相似文献

1
Setting future standards for KRAS testing in colorectal cancer.设定结直肠癌KRAS检测的未来标准。
Pharmacogenomics. 2009 Jan;10(1):1-3. doi: 10.2217/14622416.10.1.1.
2
[Clinical significance and the handling of KRAS testing on metastatic colorectal cancer].[转移性结直肠癌KRAS检测的临床意义及处理]
Nihon Rinsho. 2011 Apr;69 Suppl 3:346-50.
3
Mutation screening for KRAS and BRAF in metastatic colorectal cancer proves costly in relation to benefits.在转移性结直肠癌中对KRAS和BRAF进行突变筛查，与其获益相比成本过高。
Pharmacogenomics. 2013 Jan;14(2):124.
4
[Mutational analysis of KRAS prior to targeted therapy in colorectal cancer. Quality control of molecular pathological methods in Sweden].[结直肠癌靶向治疗前KRAS的突变分析。瑞典分子病理学方法的质量控制]
Lakartidningen. 2010;107(5):255-9.
5
Should oncologists be aware in their clinical practice of KRAS molecular analysis?肿瘤学家在临床实践中是否应该了解KRAS分子分析？
J Clin Oncol. 2011 Mar 10;29(8):e206-7; author reply e208-9. doi: 10.1200/JCO.2010.32.7700. Epub 2011 Jan 24.
6
KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.结直肠癌肿瘤中的KRAS突变特征与西妥昔单抗反应特征显著重叠。
J Clin Oncol. 2008 May 1;26(13):2228-30; author reply 2230-1. doi: 10.1200/JCO.2007.15.9186.
7
[Mutation of EGFR signaling pathway and therapy for metastatic colorectal cancer].[表皮生长因子受体信号通路突变与转移性结直肠癌的治疗]
Gan To Kagaku Ryoho. 2010 May;37(5):791-4.
8
Implementation of formalin-fixed, paraffin-embedded cell line pellets as high-quality process controls in quality assessment programs for KRAS mutation analysis.将福尔马林固定、石蜡包埋的细胞系微球作为 KRAS 突变分析质量评估计划中高质量过程控制的实施。
J Mol Diagn. 2012 May-Jun;14(3):187-91. doi: 10.1016/j.jmoldx.2012.01.002. Epub 2012 Mar 10.
9
Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies.使用预测性生物标志物来选择晚期结直肠癌患者接受表皮生长因子受体抗体治疗。
J Clin Oncol. 2008 Dec 10;26(35):5668-70. doi: 10.1200/JCO.2008.19.5024. Epub 2008 Nov 10.
10
Chemotherapy and immunotherapy in metastatic colorectal cancer.转移性结直肠癌的化疗与免疫治疗
N Engl J Med. 2009 May 14;360(20):2135; author reply 2135-6.

引用本文的文献

1
Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status.帕尼单抗治疗转移性结直肠癌：肿瘤RAS状态的重要性。
Drugs. 2015 May;75(7):731-48. doi: 10.1007/s40265-015-0386-x.
2
Optimization of routine KRAS mutation PCR-based testing procedure for rational individualized first-line-targeted therapy selection in metastatic colorectal cancer.优化常规 KRAS 基因突变聚合酶链反应检测程序，以合理选择转移性结直肠癌的一线靶向个体化治疗。
Cancer Med. 2013 Feb;2(1):11-20. doi: 10.1002/cam4.47. Epub 2013 Feb 3.
3
Comparison of COBAS 4800 KRAS, TaqMan PCR and high resolution melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas.
比较 COBAS 4800 KRAS、TaqMan PCR 和高分辨率熔解 PCR 检测方法在福尔马林固定石蜡包埋结直肠癌中检测 KRAS 体细胞突变的性能。
Virchows Arch. 2013 Mar;462(3):329-35. doi: 10.1007/s00428-013-1380-x. Epub 2013 Feb 12.
4
A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens.三种方法检测福尔马林固定结直肠肿瘤标本 KRAS 突变的比较。
Br J Cancer. 2012 Jul 10;107(2):345-51. doi: 10.1038/bjc.2012.259. Epub 2012 Jun 19.
5
Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma.用于检测结直肠癌福尔马林固定石蜡包埋组织样本中 KRAS 突变（密码子 12/13 和 61）的 PCR 检测分析性能。
Virchows Arch. 2012 Feb;460(2):141-9. doi: 10.1007/s00428-011-1180-0. Epub 2011 Dec 16.
6
Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours.基于焦磷酸测序的方法揭示了人类结直肠肿瘤中致癌基因突变负担的显著个体间差异。
Br J Cancer. 2011 Jul 12;105(2):246-54. doi: 10.1038/bjc.2011.197. Epub 2011 Jun 28.
7
Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: development and evaluation of quality by a European external quality assessment scheme.在结直肠癌的靶向治疗之前进行 KRAS 基因突变分析：一个欧洲外部质量评估计划的开发和质量评估。
Virchows Arch. 2011 Aug;459(2):155-60. doi: 10.1007/s00428-011-1094-x. Epub 2011 Jun 24.
8
External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds.需要对 KRAS 检测进行外部质量评估：建立一个欧洲计划，并报告第一届联合区域质量评估轮次。
Oncologist. 2011;16(4):467-78. doi: 10.1634/theoncologist.2010-0429. Epub 2011 Mar 26.
9
Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine.散发性结直肠肿瘤中“热点”密码子以外的 K-Ras 突变的激活——对个体化癌症治疗的影响。
Br J Cancer. 2010 Feb 16;102(4):693-703. doi: 10.1038/sj.bjc.6605534.